Advancing impurity analysis: X-ray fluorescence for small molecule drug purity validation

Are you still relying on ICP-MS or ICP-OES for elemental impurity analysis?

Discover a faster, simpler, and more cost-effective alternative in our white paper: “Advancing impurity analysis: X-ray fluorescence for small molecule drug purity validation.”

This paper introduces energy-dispersive X-ray fluorescence (ED XRF) as a powerful tool for screening elemental impurities in pharmaceutical intermediates and final drug products. Learn how Malvern Panalytical’s ED XRF spectrometers enable:

• Rapid, non-destructive analysis with minimal sample preparation
• Compliance with ICH Q3D and USP <232/233> guidelines
• Quantitative screening of 20+ regulated elements
• Up to 50% lower operational costs compared to ICP techniques
• At-line testing for faster decision-making in drug development

Whether you're working on early-phase discovery or commercial manufacturing, this white paper shows how XRF can streamline your workflow and accelerate your route to market.

Download the full white paper and see how XRF can transform your elemental analysis workflow.